IPM Take
Genetic diagnosis used to be something neurology pursued after the urgent work was finished. This study makes that sequence harder to defend. Among 175 paediatric neurology inpatients with unexplained disease, rapid whole-genome sequencing produced a phenotype-concordant diagnosis in 45.1%, with preliminary results returned in about four days. Management changed in nearly two-thirds of children with a concordant diagnosis
That turns sequencing from an academic endpoint into an acute-care decision tool. The political question is now whether hospitals are prepared to treat rapid genomics as infrastructure rather than a luxury available mainly in elite centres.
Executive Summary
The Mayo Clinic cohort included 175 children admitted to neonatal intensive care, paediatric intensive care or general paediatric wards with unexplained neurological presentations. Rapid whole-genome sequencing produced an initial phenotype-concordant diagnosis in 79 children, or 45.1%, rising to 46.9% after selected reanalysis. Diagnostic yield was higher in non-neonates than neonates.
Preliminary results were returned in a mean of 4.0 days, with final reports in about 10 days. Among children with phenotype-concordant diagnoses, management changed in 65.9%. Family history, multisystem involvement and congenital anomalies or dysmorphism were strongly associated with diagnostic success.
Why it matters
- For clinicians, rapid sequencing can end diagnostic wandering while a child is still in hospital. For families, it can replace weeks or months of uncertainty with an explanation that may immediately change medication, surveillance, counselling or treatment.
- The implementation challenge is substantial. Rapid WGS requires genomic laboratories, interpretation teams, genetic counselling and clinicians capable of acting on results. If only tertiary centres can deliver that infrastructure, genomic precision may widen the same referral inequalities it is supposed to solve.
Paediatric neurology is full of children whose symptoms tell clinicians that something is seriously wrong while conventional tests fail to explain why. Seizures, hypotonia, movement disorders, developmental regression or multisystem abnormalities may trigger repeated imaging, metabolic testing and specialist consultation before genetics finally enters the pathway.
The new JAMA Neurology study suggests that order may need to change. Rapid WGS delivered a diagnosis in almost half of the studied children and often did so quickly enough to alter care during the same admission. That is not simply an improvement in diagnostic yield. It changes the economics and ethics of uncertainty.
Every day without a diagnosis can mean another test, another empiric treatment or another family conversation built around probability rather than explanation. When a genomic result can arrive in four days and change management in most diagnosed cases, waiting until the end of the diagnostic pathway becomes increasingly difficult to justify.
The evidence comes from a single tertiary centre, and not every hospital will reproduce the same yield. But that limitation strengthens rather than weakens the policy question. If rapid genomics proves clinically valuable in expert centres, health systems need to decide how to make that capability portable rather than permanently concentrated.
Precision neurology is moving into the ward. Funding models and workforce planning now need to follow it.
